{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:05:10Z","timestamp":1792674310823,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.jare.2014.11.012","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T22:39:57Z","timestamp":1417473597000},"page":"319-330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Mesothelioma treatment: Are we on target? A review"],"prefix":"10.1016","volume":"6","author":[{"given":"Birgitta I.","family":"Hiddinga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P.","family":"van Meerbeeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jare.2014.11.012_b0005","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/sj.bjc.6690105","article-title":"The European mesothelioma epidemic","volume":"79","author":"Peto","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jare.2014.11.012_b0010","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1440-1843.2011.02020.x","article-title":"Facts. Rumours and speculations about the mesothelioma epidemic","volume":"7","author":"Van Meerbeeck","year":"2011","journal-title":"Respirology"},{"key":"10.1016\/j.jare.2014.11.012_b0015","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines for the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur Resp J"},{"key":"10.1016\/j.jare.2014.11.012_b0020","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/annonc\/mdq173","article-title":"Malignant pleural mesothelioma: ESMO clinical practical guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Stahel","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0025","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0030","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"Van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0035","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jare.2014.11.012_b0040","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1200\/JCO.2005.01.016","article-title":"What is targeted therapy?","volume":"23","author":"Sledge","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0045","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ctrv.2010.11.004","article-title":"Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?","volume":"37","author":"Agarwal","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jare.2014.11.012_b0050","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma: an immunohistochemical and molecular study with clinicopathological correlations","volume":"51","author":"Destro","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jare.2014.11.012_b0055","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/jclinpath-2011-200631","article-title":"Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma","volume":"65","author":"Enomoto","year":"2012","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jare.2014.11.012_b0060","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2014.11.012_b0065","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0070","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial","volume":"373","author":"Pirker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jare.2014.11.012_b0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(11)70318-7","article-title":"EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study","volume":"13","author":"Pirker","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0080","unstructured":"Anonymous. A study of cetuximab combined with cisplatin or carboplatin\/pemetrexed as first line treatment in patients with malignant pleural mesothelioma. [Internet] [cited 16.08.14] <http:\/\/clinicaltrials.gov\/show\/NCT00996567>."},{"key":"10.1016\/j.jare.2014.11.012_b0085","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/thx.2006.069872","article-title":"Preliminary data suggestive of a novel translocational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed","volume":"62","author":"Bertino","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.jare.2014.11.012_b0090","unstructured":"Anonymous. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in unresectable or metastatic malignant mesothelioma. [Internet] [cited 16.08.14] <http:\/\/clinicaltrials.gov\/show\/NCT00402766>."},{"key":"10.1016\/j.jare.2014.11.012_b0095","unstructured":"Anonymous. A phase II study of the association of Glivec\u00ae (imatinib mesylate, formerly known as STI 571) plus Gemzar\u00ae (gemcitabine) in patients with unresectable, refractory, malignant mesothelioma expressing either PDGFR-Beta or C-Kit. [Internet] [cited 16.08.14] <http:\/\/clinicaltrials.gov\/show\/NCT00551252>."},{"key":"10.1016\/j.jare.2014.11.012_b0100","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/JTO.0b013e318248242c","article-title":"Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and Leukemia Group B 30601): a brief report","volume":"7","author":"Dudek","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0105","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/ijc.27471","article-title":"Efficacy of anti-insuline-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlate with insulin growth factor-I receptor sites\/cell","volume":"131","author":"Kalra","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jare.2014.11.012_b0110","unstructured":"Anonymous. Phase II study of IMC-A12 in patients with mesothelioma who have been previously treated with chemotherapy. [Internet] [cited 16.08.14] <http:\/\/clinicaltrials.gov\/show\/NCT01160458>."},{"key":"10.1016\/j.jare.2014.11.012_b0115","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0120","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase II study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0125","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0130","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ajpath.2012.12.028","article-title":"New insights into understanding the mechanisms, pathogenesis, and management of malignant mesothelioma","volume":"182","author":"Mossman","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jare.2014.11.012_b0135","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.4049\/jimmunol.0901060","article-title":"Dual control of antitumor CD8 T cells through the programmed death-1\/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation","volume":"183","author":"Currie","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.jare.2014.11.012_b0140","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7\u2013H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0145","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0435","article-title":"Randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment of unresectable pleural or peritoneal mesothelioma","volume":"32:5s","author":"Maio","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0440","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.7589","article-title":"T-cell inflamed phenotype and PDL1 expression in malignant mesothelioma","volume":"32","author":"Kindler","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0160","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/JTO.0b013e3182417e44","article-title":"MET signaling: novel targeted inhibition and its clinical development in lung cancer","volume":"7","author":"Feng","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0165","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","article-title":"Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma","volume":"66","author":"Jagadeeswaran","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2014.11.012_b0445","article-title":"Phase I\u2013Ib trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients (pts) with advanced nonsquamous NSCLC or malignant pleural mesothelioma (MPM)","volume":"32:5s","author":"Zucali","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0175","unstructured":"Anonymous. A phase 2 study of ARQ 197 in patients with previously-treated malignant mesothelioma. [Internet] [cited 16.08.14] <http:\/\/clinicaltrials.gov\/show\/NCT01861301>."},{"issue":"6","key":"10.1016\/j.jare.2014.11.012_b0180","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1164\/rccm.200907-1020OC","article-title":"Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma","volume":"181","author":"Hollevoet","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jare.2014.11.012_b0185","unstructured":"Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, et al. Phase II clinical trial of amatuximab, a chimeric anti-mesothelin antibody with pemetrexed and cisplatin in advanced pleural mesothelioma. Clin Cancer Res; 2014 September 17. pii: clincanres.0804.2014. [Epub ahead of print]."},{"key":"10.1016\/j.jare.2014.11.012_b0190","doi-asserted-by":"crossref","unstructured":"Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125; Cancer 2014 July 2. doi:10.1002\/cncr.28875. epub ahead of print.","DOI":"10.1002\/cncr.28875"},{"key":"10.1016\/j.jare.2014.11.012_b0450","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jare.2014.11.012_b0200","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","article-title":"Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma","volume":"5","author":"Yasumitsu","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0205","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus active supportive care for maintenance in patients with malignant pleural mesothelioma after first-line chemothepary (NVALT5): an open-label, multicentre, randomised phase 3 study","volume":"14","author":"Buikhuisen","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0210","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.lungcan.2012.05.111","article-title":"A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma","volume":"77","author":"Dowell","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jare.2014.11.012_b0215","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bjc.2013.368","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in patients with malignant pleural mesothelioma","volume":"109","author":"Ceresoli","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jare.2014.11.012_b0220","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant pleural mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0455","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.tps7112","article-title":"IFCT-GFPC-0701 MAPS Trial, a multicenter randomized phase III trial of pemetrexed\u2013cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma (MPM)","volume":"30","author":"Zalcman","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0230","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jare.2014.11.012_b0235","unstructured":"Anonymous. A phase I\/randomized phase II study of cediranib (NSC#732208) versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma. [Internet] [cited 16.08.14] <http:\/\/clinicaltrials.gov\/show\/NCT01064648>."},{"key":"10.1016\/j.jare.2014.11.012_b0240","unstructured":"Anonymous. Phase II study of GW786034 in patients with malignant pleural mesothelioma. [Internet] [cited 16.08.14] <http:\/\/clinicaltrials.gov\/show\/NCT00459862>."},{"key":"10.1016\/j.jare.2014.11.012_b0460","article-title":"Nintedanib plus pemetrexed\/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): an international, multicenter, randomized, double-blind, placebo-controlled phase II study","volume":"32:5s","author":"Scagliotti","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0465","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.7528","article-title":"A randomized phase II study adding axitinib to pemetrexed\u2013cisplatin in patients with malignant pleural mesothelioma (MPM): clinical results of a single-center trial","volume":"31","author":"Buikhuisen","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0255","unstructured":"Anonymous. A phase II study of single-agent dovitinib in advanced malignant pleural mesothelioma which has progressed following prior platinum-antifolate chemotherapy (DOVE-M). [Internet] [cited 16.08.14] <http:\/\/clinicaltrials.gov\/show\/NCT01769547>."},{"key":"10.1016\/j.jare.2014.11.012_b0260","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2009.27.3649","article-title":"Phase II study of asparagine\u2013glycine\u2013arginine\u2013human tumour necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma","volume":"28","author":"Gregorc","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0265","unstructured":"Anonymous. NGR015: study in second line for patients with advanced malignant pleural mesothelioma pretreated with pemetrexed. [Internet] [cited 16.08.14] <http:\/\/clinicaltrials.gov\/show\/NCT01098266>."},{"key":"10.1016\/j.jare.2014.11.012_b0270","unstructured":"Anonymous. NGR019: randomized double-blind phase II study of NGR-hTNF versus placebo as maintenance treatment in patients with advanced malignant pleural mesothelioma (MPM). [Internet] [cited 16.08.14] <http:\/\/clinicaltrials.gov\/show\/NCT01358084>."},{"key":"10.1016\/j.jare.2014.11.012_b0275","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.lungcan.2013.05.006","article-title":"A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma","volume":"81","author":"Nowak","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jare.2014.11.012_b0280","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ajpath.2012.12.028","article-title":"New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas","volume":"182","author":"Mossmann","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jare.2014.11.012_b0285","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","article-title":"Molecular pathogenesis of malignant mesothelioma","volume":"34","author":"Sekido","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jare.2014.11.012_b0470","article-title":"Next-generation sequencing in malignant pleural mesothelioma: a retrospective study","volume":"32:5s","author":"Scagliotti","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0295","doi-asserted-by":"crossref","unstructured":"Zauderer MG, Bott M, Mcmillan R, Sima CS, Rusch V, Krug LM, et al. Clinical characteristics of patients with malignant pleural mesothelioma (MPM) harboring somatic BAP1 mutations. Proc IMIG 2012; Boston 12\u201314 September 2012, IIA.4.","DOI":"10.1200\/jco.2012.30.15_suppl.1541"},{"key":"10.1016\/j.jare.2014.11.012_b0300","doi-asserted-by":"crossref","unstructured":"Fennell D, Casbard A, Nixon L, Busacca S, Lester J, Griffiths G. Vinorelbine in mesothelioma (VIM): a randomised phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma (MPM) expressing BRCA1 \u2013 a study in progress. Proc IMIG; 2012, Boston 12\u201314 September, P4.29.","DOI":"10.1016\/S0923-7534(20)34088-6"},{"key":"10.1016\/j.jare.2014.11.012_b0305","unstructured":"Anonymous. Clinical and histopathologic characteristics of BAP1 mutations. [Internet] [cited 16.08.14] <http:\/\/clinicaltrials.gov\/show\/NCT01773655>."},{"key":"10.1016\/j.jare.2014.11.012_b0475","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.7083","article-title":"SWOG 0722: a phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM)","volume":"30","author":"Garland","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0480","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.e18557","article-title":"Combination efficacy of mTOR and MEK inhibitor in malignant pleural mesothelioma (MPM)","volume":"31","author":"Matsumoto","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0320","unstructured":"Anonymous. Phase II study of everolimus (RAD001) for the treatment of malignant pleural mesothelioma with merlin\/NF2 loss as a biomarker to predict sensitivity. [Internet] [cited 16.08.14] <http:\/\/clinicaltrials.gov\/show\/NCT01024946>."},{"key":"10.1016\/j.jare.2014.11.012_b0325","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1535-6108(03)00029-1","article-title":"Heat shock protein 90 as a molecular target for cancer therapeutics","volume":"3","author":"Isaacs","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jare.2014.11.012_b0330","unstructured":"Anonymous. A phase I\/II study of first line ganetespib with pemetrexed\u2013cisplatin, in patients with malignant pleural mesothelioma. [Internet] [cited 16.08.14] <http:\/\/clinicaltrials.gov\/show\/NCT01590160>."},{"key":"10.1016\/j.jare.2014.11.012_b0335","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","article-title":"Re-expression of the tumour suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK","volume":"25","author":"Poulikakos","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.jare.2014.11.012_b0485","article-title":"COMMAND: a phase II randomized, double-blind, placebo-controlled, multicenter study of defactinib as maintenance therapy in subjects with malignant pleural mesothelioma that has not progressed on at least four cycles of pemetrexed\/platinum therapy","volume":"32:5s","author":"Fennell","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0345","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat Rev Cancer"},{"issue":"suppl 2","key":"10.1016\/j.jare.2014.11.012_b0350","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0959-8049(11)70098-3","article-title":"VANTAGE 014: vorinostat in a phase III, randomized, double-blind, placebo-controlled trial","volume":"47","author":"Krug","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jare.2014.11.012_b0355","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1165\/rcmb.2009-0206TR","article-title":"Asbestos, lung cancers, and mesotheliomas","volume":"42","author":"Heintz","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jare.2014.11.012_b0360","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.onc.1210744","article-title":"BCL-2 family regulation by the 20S proteasome inhibitor bortezomib","volume":"27","author":"Fennell","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.jare.2014.11.012_b0365","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1097\/JTO.0b013e318260dfb9","article-title":"Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma","volume":"7","author":"Fennell","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0370","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1016\/j.ejca.2013.05.008","volume":"49","author":"O\u2019Brien","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jare.2014.11.012_b0375","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2009.25.9275","article-title":"Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy","volume":"28","author":"Righi","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0380","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/ijc.25202","article-title":"Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer","volume":"126","author":"Delage","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jare.2014.11.012_b0385","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-06-1101","article-title":"In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion","volume":"12","author":"Szlosarek","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2014.11.012_b0490","article-title":"Randomized trial of arginine deprivation with pegylated arginine deiminase in patients with malignant pleural mesothelioma","volume":"32:5s","author":"Szlosarek","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0395","article-title":"Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase","volume":"7","author":"Szlosarek","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0400","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.4049\/jimmunol.1300448","article-title":"A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody","volume":"190","author":"Abe","year":"2013","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.jare.2014.11.012_b0405","doi-asserted-by":"crossref","first-page":"e89146","DOI":"10.1371\/journal.pone.0089146","article-title":"CARP-1 functional mimetics are a novel class of small molecule inhibitors of malignant pleural mesothelioma cells","volume":"9","author":"Jamal","year":"2014","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.jare.2014.11.012_b0410","doi-asserted-by":"crossref","first-page":"e90374","DOI":"10.1371\/journal.pone.0090374","article-title":"Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins \u03b1v\u03b23 and \u03b1v\u03b25","volume":"9","author":"Cheng","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jare.2014.11.012_b0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1349-7006.2009.01336.x","article-title":"Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells","volume":"101","author":"Sekido","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jare.2014.11.012_b0420","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/bjc.2014.220","article-title":"Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma","volume":"110","author":"Zhou","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jare.2014.11.012_b0425","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jare.2014.11.012_b0430","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2012.06.011","article-title":"Cediranib in patients with malignant pleural mesothelioma: a phase II trial of the University of Chicago Phase II Consortium","volume":"78","author":"Campbell","year":"2012","journal-title":"Lung Cancer"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123214001453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123214001453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:41:09Z","timestamp":1761856869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123214001453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S2090123214001453"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2014.11.012","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesothelioma treatment: Are we on target? A review","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2014.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}